Carregant...
Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field
Triple negative breast cancers (TNBCs) represent 10%–20% of primary breast cancers, and despite having greater initial sensitivity to cytotoxic chemotherapy, patients with TNBCs have higher rates of distant metastasis and a poorer prognosis compared with patients with hormone receptor positive and/o...
Guardat en:
| Publicat a: | Oncologist |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
AlphaMed Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5599192/ https://ncbi.nlm.nih.gov/pubmed/28559413 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0095 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|